| Product Unit Size | Cost | Quantity | Stock |
|---|
IPI-549 is a selective inhibitor of the γ isoform of PI3K (PI3Kγ). It is being investigated along with nivolumab, an immune checkpoint inhibitor, as an immuno-oncology treatment for advanced solid tumors. IPI-549 reprograms macrophages to an immune-activating phenotype in preclinical studies.
| Cas No. | 1693758-51-8 |
|---|---|
| Purity | ≥98% |
| Formula | C30H24N8O2 |
| Formula Wt. | 528.58 |
| Chemical Name | IPI-549 |
| IUPAC Name | 2-Amino-N-[(1S)-1-{8-[(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-1,2-dihydro-3-isoquinolinyl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| Synonym | IPI 549, IPI549 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Evans C., Liu T., et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 7(9):862-7 (2016). PMID: 27660692.
De Vera A., Gupta P., et al. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Lett. 442:91-103 (2019). PMID: 30391357.